OBJECTIVE: We report our own experience with the use of hyperbaric oxygen (HBO) for the management of postradiation hemorrhagic cystitis. METHODS: We reviewed retrospectively 14 patients from 2001 to 2007 with different pelvic organ malignancies who developed radiation cystitis after irradiation. Patients received 100% oxygen in a hyperbaric chamber at a pressure of 2.5 atmospheres absolute, 60 min bottom time, once a day, 7 days a week for at least 1 month. In principle, 30 HBO treatments per course were performed. After every course of HBO treatments, therapeutic effect was evaluated. The mean duration of follow-up of all patients was 18 months (range: 1-6 years). RESULTS: Patients were divided into 2 groups, group 1 (treatment group, n = 10) and group 2 (without treatment, n = 4). The mean duration between the onset of hematuria and the beginning of HBO therapy was 8.9 months (range: 3-34). Group 2 did not receive HBO because they were not healthy enough. Only 2 patients (20%) of group 1 recovered from their hemorrhagic cystitis. Group 1 had a significantly lower cure rate of postirradiation hemorrhagic cystitis in comparison to group 2. CONCLUSIONS: Our experience with the use of HBO did not yield favorable results. Randomized well-controlled studies are needed. Copyright (c) 2010 S. Karger AG, Basel.
OBJECTIVE: We report our own experience with the use of hyperbaric oxygen (HBO) for the management of postradiation hemorrhagic cystitis. METHODS: We reviewed retrospectively 14 patients from 2001 to 2007 with different pelvic organ malignancies who developed radiation cystitis after irradiation. Patients received 100% oxygen in a hyperbaric chamber at a pressure of 2.5 atmospheres absolute, 60 min bottom time, once a day, 7 days a week for at least 1 month. In principle, 30 HBO treatments per course were performed. After every course of HBO treatments, therapeutic effect was evaluated. The mean duration of follow-up of all patients was 18 months (range: 1-6 years). RESULTS:Patients were divided into 2 groups, group 1 (treatment group, n = 10) and group 2 (without treatment, n = 4). The mean duration between the onset of hematuria and the beginning of HBO therapy was 8.9 months (range: 3-34). Group 2 did not receive HBO because they were not healthy enough. Only 2 patients (20%) of group 1 recovered from their hemorrhagic cystitis. Group 1 had a significantly lower cure rate of postirradiation hemorrhagic cystitis in comparison to group 2. CONCLUSIONS: Our experience with the use of HBO did not yield favorable results. Randomized well-controlled studies are needed. Copyright (c) 2010 S. Karger AG, Basel.
Authors: James Cardinal; Austen Slade; Mary McFarland; Sorena Keihani; James N Hotaling; Jeremy B Myers Journal: Curr Urol Rep Date: 2018-04-13 Impact factor: 3.092
Authors: Heather Payne; Andrew Adamson; Amit Bahl; Jonathan Borwell; David Dodds; Catherine Heath; Robert Huddart; Rhona McMenemin; Prashant Patel; John L Peters; Andrew Thompson Journal: BJU Int Date: 2013-11 Impact factor: 5.588